Promotive Communications

Laboratory Focus May 2011

Laboratory Focus is Canada's leading editorial-based lab publication. Providing readers with the latest technology updates through application and tech notes, as well as covering new products and trends in laboratories across Canada.

Issue link:

Contents of this Issue


Page 0 of 19

P h a r mac e u t i cal C l i n i cal C h e m i cal food w w w. b i o s c i e n c e w o r l d . c a iPS Cell Generation Characterizaation and Disease Modeling Page 8 environment May 2011 Volume 15, Number 3 Liquid Chromatography Analysis Sweeteners and Additives in Beverages Page 11 R&D News.......................... 1 Appointments..................... 6 Pharma Notes. ................... 7 . New Products................... 14 Calendar........................... 17 Career Spotlight............... 18 Sanofi-Aventis funds innovative Canadian cancer research Over two million dollars of support has helped to create one of the world���s most successful tissue-based biomarker laboratories Sanofi-aventis funds innovative Canadian cancer research. From left to right; Dr. Torsten Nielsen (Co-director, GPEC), Maureen Dodd (sanofi-aventis), Monique Furlan (sanofi-aventis), Doug Nelson (President & CEO, BC Cancer Foundation), Dr. David Huntsman (Co-director GPEC), Dr. Blake Gilks (Co-director GPEC), Brian Eccleston (sanofi-aventis), Stan Glezer (sanofi-aventis). Photo: CNW Group/sanofi aventis The Genetic Pathology Evaluation Centre (GPEC) has produced some of the most significant and Publications Mail Registration Number: 40052410 groundbreaking oncology research in Canada. To celebrate these achievements, sanofi-aventis has announced that the support they have provided to the lab over time has now surpassed $2 million. Developed in late 2001, GPEC is a collaborative research venture of the Pathology Department at Vancouver General Hospital (VGH), the Vancouver Prostate Centre at VGH, and the BC Cancer Agency (BCCA). GPEC is supported through an unrestricted research grant from sanofi-aventis in Canada. ���GPEC researchers are pushing forward practical innovation with an emphasis on translational research and quality assurance for clinical genetic testing. This ensures scientific advancements are applied directly to patient care and improve the quality of that care,��� said Stan Glezer, VP Medical, sanofi-aventis Canada Inc. Under the leadership of Dr. Blake Gilks, Dr. David Huntsman and Dr. Torsten Nielsen, GPEC is responsible for a number of important cancer related initiatives, including a Canada-wide quality assurance initiative that provides a measurement of accuracy in lab testing where there was none previously. This helps labs across the country do a better job serving the needs of patients and improves the ability of oncologists to find the best treatment for each cancer patient. In addition, GPEC is leading an international study to look into the introduction of additional markers for breast and other cancers to be used in everyday clinical practice, above and beyond estrogen and progesterone receptors and HER2. The lab has generated more than 250 publications over the past 10 years. GPEC is uniquely positioned as a cancer research organization due to their state-of-the-art genetic analytical platform that is linked to the province���s tissue sample biobank and patient treatment/ outcomes data that is made available through the BCCA population based cancer management program. The support provided by sanofi-aventis to GPEC has Continued on page 2

Articles in this issue

Links on this page

view archives of Promotive Communications - Laboratory Focus May 2011